The discovery of regulatory small RNAs continues to reshape paradigms in both molecular biology and virology. Here we describe examples of influenza A virus-derived small viral RNAs (svRNAs). svRNAs are 22-27 nt in length and correspond to the 5′ end of each of the viral genomic RNA (vRNA) segments. Expression of svRNA correlates with the accumulation of vRNA and a bias in RNAdependent RNA polymerase (RdRp) activity from transcription toward genome replication. Synthesis of svRNA requires the RdRp, nucleoprotein and the nuclear export protein NS2. In addition, svRNA is detectable during replication of various influenza A virus subtypes across multiple host species and associates physically with the RdRp. We demonstrate that depletion of svRNA has a minimal impact on mRNA and complementary vRNA (cRNA) but results in a dramatic loss of vRNA in a segment-specific manner. We propose that svRNA triggers the viral switch from transcription to replication through interactions with the viral polymerase machinery. Taken together, the discovery of svRNA redefines the mechanistic switch of influenza virus transcription/replication and provides a potential target for broad-range, anti-influenza virus-based therapeutics.
microRNA | replicase | replication switch | RNA dependent RNA polymerase | transcriptase I nfluenza A virus is a seasonal pathogen responsible for significant morbidity and mortality worldwide (1) . The virus is encoded by eight individual single-stranded segments of RNA with negative polarity that localize to the nucleus upon viral entry (1) . Each of the eight RNA segments is encapsidated by the nucleoprotein (NP) and associates with the RNA-dependent RNA polymerase (RdRp, composed of polymerase subunits PA, PB1, and PB2) to form a viral ribonucleoprotein (RNP) complex, the machinery responsible for both transcription and replication (2) . Each RdRp subunit is thought to play a distinct and essential role within the polymerase. Although extensive functional analyses have elucidated many aspects of the overall RdRp structure, little is known regarding control of RNA synthesis (3) (4) (5) (6) (7) (8) (9) .
The RNA promoter for the influenza virus RdRp consists of 13 and 12 conserved nucleotides at the 5′ and 3′ ends of the vRNA, respectively (10, 11) . These noncoding regions (NCRs), along with additional segment-specific bases, form a double-stranded panhandle/corkscrew structure recognized by the RdRp (12) (13) (14) (15) (16) . The RdRp associates with the secondary structure of the viral NCRs and initiates transcription beginning at the first 3′ cytosine (17) . The PB2 component of the RdRp usurps host mRNAs, and PA cleaves the message ≈10-13 bases downstream of the 5′ cap; this fragment then is used by PB1 as a primer to synthesize viral mRNA (4, 8, (17) (18) (19) (20) . Subsequent elongation of the transcript, like initiation, is dependent on a stable association with the 5′ vRNA end (21) . As the RdRp reaches the 5′ end of the looped fragment, its association with the 3′ NCR imposes a steric hindrance on the polymerase as it transcribes a uracil-rich region (22, 23) . This restrictive mobility results in stuttering of the polymerase, generation of a polyadenylated tail, and the production of viral mRNA (2, 24) . Taken together, this transcriptase activity, composed of PA and PB2 cap-snatching and PB1 polymerase function, is dependent on the utilization of the secondary structure of the vRNA for proper synthesis of viral mRNAs.
Accumulation of viral mRNA, and subsequent protein production, must be followed by a switch to viral replicase activity for generation of new vRNA and assembly of progeny virions. However, because mRNA transcripts are incomplete copies of the vRNA, they cannot be used as substrates for genomic synthesis (1) . Instead, vRNA synthesis takes place through a cRNA intermediate, also made by the RdRp from vRNA but representing a full-length complement of the vRNA. Thus, the virus must prioritize its replicative cycle to bias mRNA synthesis early in infection, switching to the production of vRNA when new virions are to be assembled (25) . A number of studies have identified key components that influence the viral switch to replication; these components include cRNA stability, the intracellular levels of nucleotides, and the soluble fractions of NP and/or the RdRp (25) (26) (27) (28) .
In contrast to transcription, the replicase activity of the RdRp generates vRNA and cRNA in a primer-independent manner (25) , resulting in the synthesis of the NCRs with 5′ triphosphate ends (29) . For the replicase to extend to and copy the 5′ vRNA NCR, the secondary structure of the viral segment must release the steric hindrance used during transcriptase activity, thus preventing stuttering and polyadenylation. Although genome synthesis does not require polyadenylation, studies demonstrate the need for the association of both the 3′ and 5′ NCRs throughout virus replication (13, 22, 30) . To fulfill genome end association while permitting complete RNA synthesis, the virus must provide in some way for a double-stranded motif to reconstitute the promoter. Because current models fail to reconcile this paradox, a true underlying mechanism for the switch from transcriptase to replicase activity remains elusive.
Results
Small RNA Deep Sequencing from Influenza A Virus-Infected Cells.
Because many viruses are known to produce small RNAs that aid in aspects of their viral life cycle (31, 32) , we speculated that influenza A virus also may generate such products. Given the need for a double-stranded RNA promoter in the context of a singlestranded genome, a small RNA could serve to reconstitute promoter functionality. In contrast, a small RNA could be incorporated into the RdRp to modify its replicase activity, similar to many cellular RNP complexes.
To investigate if influenza A virus produced such small RNAs, we performed deep sequencing on influenza A/PR/8/34 (H1N1) virus-infected lung epithelial cells. Twelve hours postinfection (hpi), total RNA was resolved by polyacrylamide gel electrophoresis (PAGE), and RNA (10-40 nt in length) was isolated and processed using SOLiD (Applied Biosystems) deep sequencing methods (33) . Upon analyzing more than 4 million unique reads, we found that more than 90% of the sequences were composed of cellular microRNAs (miRNAs) (34) . However, a small percentage of the total captured sequences in infected cells derived directly from influenza A virus (Table S1 ). Although most of these small RNAs comprise viral breakdown products, which are distributed equally across the viral genome in both polarities, 30% of the influenza A virus sequences captured in this size fraction were significantly enriched for the 5′ end of the vRNA (Fig. 1 and Table S2 ). Influenza A virus-derived small RNAs (svRNAs) ranged from 22-27 nt in length, were unique to each of the eight segments at positions 14-16 and beyond the 21st base, and terminated three to four bases from the polyU tract (Table S3) . Moreover, because these RNA species likely contain a 5′ triphosphate, their inefficient ligation during sample preparation would result in a gross underestimate of the percentage of svRNA in the total RNA captured during sequencing (35) . Overall, the predominant species lengths were 25 nt (segments 2, 3, 6, 7, and 8) and 27 nt (segments 1, 4, and 5) (Table S3) .
Characterization of svRNA Expression. To ascertain whether svRNA was produced at significant levels for detection by Northern blot, and to determine the kinetics of svRNA synthesis, we performed time-course studies in infected lung epithelial cells. To monitor total svRNA produced during the course of infection, a panspecific probe, capable of hybridizing to each of the eight svRNAs, was generated. Total svRNA expression demonstrated accumulation at ≈12 hpi and increased in concentration for the duration of the experiment (Fig. 2A) . Although viral RNA breakdown products, which also were reflected in the deep sequencing results, were evident by Northern blot, the predominant accumulation of small RNA products between 22 and 25 nts in length corroborated the abundance of this 5′ small RNA. To ascertain how the kinetics of svRNA synthesis correlated to viral transcription, the nonstructural 1 (NS1) protein levels were determined by Western blot (Fig. 2B) . These levels demonstrated that protein expression, visible within 8 hpi, preceded the detection of svRNA. Furthermore, quantitative PCR (qPCR) using a reverse transcription strategy selective for genomic viral RNA demonstrated a dramatic switch to viral replication at 12 hpi, concurrent with the appearance of svRNA (Fig. 2C ). To ensure that svRNA was specific to influenza A virus and was not a virus-or IFN-inducible miRNA, we analyzed total RNA from lung epithelial cells treated with vesicular stomatitis virus (VSV) or type I IFN (IFN-I) . Northern blot analysis demonstrated the appearance of influenza A virusspecific svRNAs of 22 and 25 nts that were absent in both VSVand IFN-I-treated samples (Fig. 2D ). To ensure that svRNA was not specific to a particular influenza A virus subtype, we isolated total RNA from 10-day-old eggs inoculated with H1N1 (A/PR/8/ 34), H3N2 (A/Panama/2007/99), and H5N1 (A/Vietnam/1203/04) and analyzed them for the generation of svRNA. Analysis of total RNA demonstrated that svRNA was produced by all three influenza A virus subtypes in the context of an in ovo infection (Fig.  2E) ; these overall levels correlated with the extent of virus replication (Fig. S1A) . Furthermore, H1N1 infection of human, canine, and murine fibroblasts also resulted in the generation of svRNA (Fig. 2F) . Collectively, these data indicate that svRNA is an abundant virus-specific RNA species, it is produced by a broad range of influenza A virus subtypes, its production is not cell-or species-specific, and generation corresponds to a shift from viral transcription to replication.
svRNA Production in Trans Requires RdRp Activity, NP, and Nuclear Export Protein NS2. To investigate how svRNA species are generated, we determined what viral components were required for its production. To this end, bidirectional plasmids representing each of the eight viral segments were transfected into fibroblasts (Fig.  S1B ). Because each segment-specific plasmid produces an RNA polymerase I-dependent vRNA (3′ to 5′ RNA of negative polarity with a 5′ triphosphate and no polyA tail) and a polymerase II-dependent mRNA (5′ to 3′ RNA of positive polarity with both a 5′ cap and a 3′ polyA) tail, transfection serves both as a template source of vRNA and to express segment-specific proteins (36) . To determine whether svRNA could be generated in the absence of virus infection and to ascertain which viral proteins were required for its processing, each of the eight bidirectional segment-specific plasmids was transfected into fibroblasts, and total RNA was analyzed by Northern blot (Fig. 3A) . As compared with mock treatment, transfection of each of the influenza A virus segments induced robust expression of svRNA. In contrast, removal of segments 1 (PB2), 2 (PB1), 3 (PA), or 8 [which encodes NS1 as well as the nuclear export protein (NEP)/nonstructural protein 2 (NS2)] resulted in a complete loss of svRNA. Removal of segments 4 and 6, encoding HA and neuraminidase (NA), resulted in no significant changes. Loss of segment 7, encoding the matrix proteins M1 and M2, although demonstrating a decrease in svRNA production, did not have the dramatic loss observed for segments 1-3 and 8. Interestingly, loss of segment 5, which encodes NP, resulted in the loss of svRNA but the production of two fragments of ∼32 and ∼42 nt. To ensure that the bidirectional plasmids produced each of their respective transcripts in trans, qPCR was performed on NP, M, and PB2 ( Fig. S1 C-E). In each case, loss of PB2 and PB1 expression caused a dramatic decrease in NP and M expression levels, indicating that the majority of mRNA from these transcripts was produced from the RdRp rather than directly from the transfected bidirectional plasmid. These data confirm that influenza A virus produces a specific small RNA during infection in an RdRp-dependent manner, suggests a possible structural role for NP, and implicates an unknown requirement for segment 8 vRNA, NS1, and/or NEP/NS2. To elucidate further the role for segment 8 products in the generation of svRNA, segments 1-7 were coexpressed with plasmids expressing either NS1 or NEP/NS2 mRNA (Fig. 3B ). The expression of NS1 failed to rescue svRNA production, but expression of NEP/NS2 demonstrated a partial rescue. Taken together, these data suggest that NEP/NS2 provides an essential component of the viral machinery responsible for the generation of svRNA. Furthermore, given the recent implication of NEP/NS2 in genome replication (37, 38) , the total requirement for the RdRp, NP, and NEP/NS2 strongly suggests that a functional polymerase and vRNA template are the minimal components for the production of svRNA.
svRNA Physically Associates with RdRp. To determine whether any of the known RNA-binding protein components physically associated with svRNA, Flag-tagged GFP and the influenza A virus proteins PB2, PB1, PA, RdRp (PB1/PB2, and PA), NP, and NS1 were cotransfected with a nonstructural (NS) svRNA mimetic containing a 5′ triphosphate (pNS) (Fig. 3C, Figs . S1F and S2). Flag immunoprecipitation, followed by small RNA Northern blot assay, demonstrated that svRNA associated only with the complete RdRp (PB1, PB2, and PA) and not with any individual polymerase component. Furthermore, bound svRNA contained both a 5′ triphosphate and a less dominant species lacking such a motif, as corroborated through phosphatase treatment (Fig. 3D) .
A B svRNA Does Not Induce the Cell's Autonomous Antiviral Defenses.
Because the pattern recognition receptor retinoic acid-inducible gene 1 has been found to associate with 5′ triphosphate-containing RNAs, we evaluated whether svRNAs, which likely contain a 5′ triphosphate, act as pathogen-associated molecular patterns. To determine the cellular response to svRNA, we compared the pNS svRNA mimetic with unphosphorylated NS protein svRNA, scrambled (Scbl) RNA controls, or phosphorylated scrambled (pScbl) (Fig. S2) . To ensure that these oligonucleotides were comparable to endogenous svRNA, RNA from infected cell extract was compared with extract from fibroblasts transfected with each of the four RNA oligonucleotides and evaluated with an svRNA-specific probe (Fig. S3A) . Northern blot analysis confirmed the delivery of NS and pNS and demonstrated their similarity to endogenous svRNA, migrating at the higher 25-nt position of svRNA instead of the 22-nt predominant svRNA visualized by the pan-specific probe (Fig. S3A) . Despite the robust levels achievable by transfection and the presence of an exposed 5′ triphosphate, svRNA failed to induce phosphorylation of IFN regulatory factor 3 (IRF3) (Fig. S3B) . In contrast, either transfection of the dsRNA mimetic, polyinosinic:polycytidylic acid (polyIC), or infection with an influenza A virus encoding an NS1 RNA-binding mutation (mFlu) (39) induced strong IRF3 phosphorylation, induction of IFN-β, and the subsequent regulation of known IFNand virus-stimulated genes (Fig. S3B ) (40) . These results are consistent with the model that cellular antiviral helicases require an exposed 5′ triphosphate, with additional secondary structure and length requirements (41-43).
Anti-svRNA Induces Loss of vRNA and Inhibits Viral Spread. Because svRNA does not appear to be a by-product of the cell's antiviral defenses, we investigated whether it was a functional component of the viral life cycle. Because inhibiting mRNA synthesis would be detrimental to overall viral replication, we reasoned that svRNA would bias cRNA/vRNA synthesis only moderately, but its inhibition would result in a dramatic loss of genomic RNA. To analyze the impact of svRNA inhibition on RNA replication, we synthesized a locked nucleic acid (LNA) anti-svRNA, complementary to segment 4 svRNA (anti-HA) (44) . We transfected Scbl LNA or anti-HA and performed a de novo infection with influenza A/PR/8/34 (H1N1) virus and analyzed the levels of HA mRNA, cRNA, and vRNA by primer extension (Fig. 4A) . These results demonstrated that anti-HA had low impact on both HA mRNA and cRNA but induced a significant reduction in HA vRNA.
To ascertain whether loss of vRNA in the absence of soluble svRNA is observed during a single-cycle infection, we transfected Scbl LNA or anti-HA and monitored protein production directly following the inoculation of influenza A/PR/8/34 virus. Treatment with anti-HA had no impact on NP or NS1 protein levels following transfection but induced a modest decrease in HA protein, likely the result of loss of segment 4 vRNA (Fig. 4B) . However, the supernatant from these initial infections demonstrated a dramatic decrease in viral progeny when applied to target Madin-Darby canine kidney (MDCK) cells (Fig. 4C) . Because efficient influenza A virus egress requires RNP association (45), the near total loss of HA, NP, and NS1 in the target MDCK cells suggests a defect in packaging, possibly because of the loss of HA vRNA. This possibility is supported further by the fact that HA vRNA packaging sequences are essential components required for viral egress (46) .
svRNA Function Is Segment-Specific. To determine whether blocking svRNA resulted in the inhibition of vRNA synthesis in a segment-specific manner, anti-NA and -NS svRNA LNAs were synthesized and evaluated in the context of a de novo infection by primer extension (Fig. 5A) . These results demonstrated that only loss of HA svRNA impacted HA transcripts. Although a modest decrease of mRNA was observed in the presence of anti-HA, a robust loss of vRNA was evident. In contrast, anti-NA or -NS svRNA LNAs had no significant impact on any HA transcripts.
To corroborate svRNA segment specificity further, we determined whether prolonged treatment with anti-HA would result in only a specific loss of HA vRNA and the consequential loss of HA mRNA and protein. In comparison with no treatment or with delivery of Scbl LNA, anti-HA induced a dramatic loss of HA expression but had no significant impact on NP or NS1 protein levels (Fig. 5B) . Furthermore, viral growth curves in the presence of either Scbl or HA-specific anti-svRNA corroborated the loss of viral protein production, because titers were reduced by 80% (Fig. 5C ). Taken together, the data presented support a model in which svRNA expression impacts the transition from transcriptase to replicase activity and further suggest that it may function in a segment-specific manner.
Discussion
The identification of influenza A virus svRNAs elucidates a unique mechanism by which a virus can control the switch between transcription and replication. Although many details concerning the biogenesis and molecular properties of influenza A virus svRNA remain to be determined, its discovery suggests viruses, like the cell, can use RNA to bridge the nucleic acid-protein interface, as seen for splicing, telomere maintenance, and even translation (47) . Furthermore, although we do not have reason to suspect that svRNAs act as miRNAs, the ability to synthesize such small RNA species suggests that RNA viruses may transcribe such products routinely in an effort to control infection.
With respect to svRNA synthesis, RdRp could cleave vRNA segments or could synthesize svRNA from cRNA. Cleavage of vRNA, although the most rapid means of generating svRNA, is unlikely, because this cleavage would destroy the genomic template and therefore would be detrimental to the viral life cycle. Alternatively, synthesis from cRNA is possible but would demand a stochastic event in which cRNA was produced in an svRNAindependent manner. This latter model is supported by data suggesting that cRNA stability is critical for the viral switch from transcription to replication and would explain why blocking svRNA results mainly in a selective loss of vRNA (27) . If the source of svRNA does indeed require stochastic, svRNA-independent cRNA synthesis, perhaps NP function is required to block temporally the secondary structure of the panhandle and allow complete cRNA synthesis. This requirement would help explain why NP accumulation also has been associated with the switch from transcription to replication (48) .
Interestingly, the requirement for NEP/NS2 in the generation of svRNA supports the idea that svRNA aids in the formation of an alternative RdRp replicase complex, an attribute recently bestowed upon NEP/NS2 (38) . Furthermore, the finding that NEP/NS2 participates in the generation of svRNA may indicate that this viral protein is involved not only in RNA trafficking but also in the switch between transcription and replication. In this context, the RdRp replicase would consist of an NEP/NS2-containing RdRp bound to svRNA, and the transcriptase would lack svRNA. Because svRNA regulates vRNA replication in a segment-specific manner, this model implies the existence of eight different RdRp replicases, as determined by the svRNA loaded into the replication complex. The physical association of the RdRp with svRNA within the replicase could serve as a segment-specific guide capable of reconstituting the promoter in trans, thereby permitting access to the genomic ends. In contrast, lack of svRNA in the transcriptase would permit the stuttering needed to generate the polyA tail during viral mRNA synthesis, because the RdRp remains bound in cis to the 5′ end of the vRNA template.
Another remaining question pertaining to svRNA is length. Although SOLiD-based deep sequencing data suggest that the two prominent species are 25 and 27 nt in length, Northern blot analysis clearly indicates sizes of ≈22 and 25 nt. Although this discrepancy is difficult to explain, it may be related to the 5′ triphophosphate motif of svRNA, which would affect both its cellular stability and migration properties. Whatever the exact length of the segment-specific svRNAs, the heterogeneity of the sequencing data suggests that the processing may be somewhat stochastic, resulting in quasispecies of svRNAs.
In conclusion, these data support a model in which svRNA regulates the levels of vRNA synthesis during de novo virus infection. Although the molecular mechanism underlying svRNA function requires further study, it is clear that its presence is essential in converting the RdRp from a transcriptase to a replicase. Given the occurrence of annual influenza virus epidemics and the potential threat for periodic pandemics, our results set the foundation for understanding the intricacies of influenza virus infection and provide targets for broad-spectrum influenza anti-virals.
Materials and Methods
Cell Culture and Viral Infections. Cell collections and growth conditions can be found in the SI Materials and Methods.
Deep Sequencing. Deep sequencing was performed on human alveolar basal epithelial cells (A549) untreated or infected with influenza A/PR/8/34 at a multiplicity of infection (MOI) of 1.0 for 12 h. RNA smaller than 40 nt was isolated from total RNA samples using a FlashPAGE fractionator (Ambion), and SOLiD small RNA libraries were prepared using the SOLiD Small RNA Expression Kit (Ambion). Complete materials and methods are given in SI Materials and Methods.
svRNA Detection. Detection of svRNA was performed by Northern blot in a manner similar to that previously described for miRNAs (49) . Briefly, RNA was resolved on a 15% denaturing polyacrylamide gel containing 7.5 M urea and 20 mM 3-(N-morpholino)propanesulfonic acid-NaOH (pH 7) and transferred to Hybond NX membrane. Chemical crosslinking was performed per the above-mentioned protocol for 1 h at 60°C, blocked for I h at 65°C in 6× SSC and 7% SDS, and subsequently probed with radiolabeled oligodeoxyribonucleotides. Methods used in probe design and labeling can be found in SI Materials and Methods . that were mock-transfected or transfected with 25 nM Scbl LNA or HA-, NA-, or NS-anti-svRNA. Twelve hours posttransfection, cells were infected with A/PR/8/ 34 at an MOI of 10 in Opti-MEM, and total RNA was harvested at the indicated times and subjected to RT-PCR using previously published primers (50 Deep Sequencing. Deep sequencing was performed on A549 cells untreated or infected with influenza A/PR/8/34 at an MOI of 1.0 for 12 h. RNA smaller than 40 nt was isolated from total RNA samples using a FlashPAGE fractionator (Ambion), and SOLiD small RNA libraries were prepared using the SOLiD Small RNA Expression Kit (Ambion). Briefly, RNA adaptors were ligated to small RNAs, reverse transcription was performed with ArrayScript (Ambion), and the cDNA was treated with RNase H. The cDNA library was amplified by PCR using 18 cycles and sizeselected for ∼105-to 130-bp products on a 6% PAGE gel. The resulting libraries were quantified on a Flashgel (Lonza) using a Quant Ladder (Lonza) and assayed for quality on a Bioanalyzer (Agilent). The libraries were amplified onto SOLiD sequencing beads by emulsion PCR using the SOLiD ePCR Kit (Applied Biosystems). The templated beads were isolated, enriched, and deposited into an eighth of a SOLiD sequencing slide (Applied Biosystems) using the SOLiD Bead Deposition Kit (Applied Biosystems). The slides were sequenced on a SOLiD Version 3 (Applied Biosystems). Color-space base calling and quality value assignment were performed on the SOLiD oninstrument cluster. The resulting reads were processed using the SOLiD Small RNA Analysis Tool (Applied Biosystems). Basespace reads were generated from color-space reads using the SOLiD System GFF Conversion Tool. The sequences were translated from color space to sequence space allowing up to two mismatches to the viral genome segments. The sequences and mappings were stored in a relational database (MySQL; http:// www.mysql.com) and analyzed using custom scripts written in Perl. The density of mappings across the segments allowed us to identify the peaks at the ends of the segments.
Small Viral RNA Detection. Probes were designed as follows: panspecific DNA oligo complementary to the 5′ noncoding region of influenza A viral RNA (vRNA): 5′-AAAAANNNCCTTGTTT-CTACT-3′ and control anti-U6 5′-GCCATGCTAATCTTCTCT-GTATC-3′. T4 polynucleotide kinase (Invitrogen) and [γ- ATP (Perkin-Elmer) were used to radiolabel the probes, which subsequently were purified by Sephadex G-25 columns (GE Healthcare), and resulting blots were imaged overnight by autoradiogram. All depicted Northern blots are representative results of multiple experiments. For plasmid-based generation of small viral RNA (svRNA), bidirectional plasmids driven by both RNA polymerase I and RNA polymerase II (a kind gift from P. Palese, Mount Sinai School of Medicine, New York) were used, resulting in the production of vRNA and mRNA, respectively, for each individual segment. HEK293 cells were mock transfected or transfected with indicated combinations of bidirectional plasmids (1 μg DNA for each segment) using Lipofectamine 2000 (Invitrogen) in Opti-MEM medium (GIBCO). Total RNA was harvested 24 h posttreatment and analyzed by Northern blot or was DNase treated (DNase I; Roche), reverse transcribed with SuperScript II (Invitrogen), and analyzed by quantitative RT-PCR (qRT-PCR). For nonstructural protein 1 (NS1) and nuclear export protein (NEP)/nonstructural protein 2 (NS2) reconstitution, segments 1-7 (500 μg/segment) were cotransfected with 4 μg of plasmid expressing either NS1 or NEP/NS2. Twenty-four hours after transfection, total RNA was harvested and analyzed as previously described.
Synthetic svRNA and Anti-svRNA Locked Nucleic Acid Oligonucleotides. Standard synthesis cycles were used for detritylation, phosphoramidite coupling, oxidation, and capping steps. We used 2′-O-TBDMS-3′-O-(cyanoethyl-N,N-diisopropyl) phosphoramidites bearing fast labile nucleobase-protecting groups (i.e., Ac for C, Pac for A, iPrPac for G) from ChemGenes as 0.2-M solutions in anhydrous acetonitrile (Glen Research). The capping reagent was Pac 2 O. A trityl-off synthesis was performed. In the final step, oligonucleotides were washed with anhydrous acetonitrile and reverse flushed with argon. If oligonucleotides were not to be phosphorylated, the oligonucleotide on solid support was treated with ammonia, then with tetrabutylammonium fluoride (TBAF), and then purified, as described below. To phosphorylate oligonucleotides, 2 μmol of oligonucleotide on solid support was placed in a dry Twist synthesis column (Glen Research). The column was closed and flushed with argon. The oligonucleotide on solid support was treated with a pyridine solution of monophosphorylation reagent and then was treated for 30 h with a 0.5-M solution of Tris(tributylammonium) pyrophosphate (Aldrich) in anhydrous N,N-dimethylformamide (Aldrich) dried over activated molecular sieves for 24 h. The column was flushed and washed several times with methanol and acetonitrile, followed by a reverse flush with argon. The dried controlled pore glass solid supported oligonucleotide was transferred to an empty screw-cap plastic vial (10 mL), and 3 mL of 30% NH 4 OH (J.T.Baker)/absolute ethanol (3:1, vol/vol) was added and left to react for 2 h at room temperature. The solution was filtered and freeze-dried. Deprotection of the 2′ t-butyldimethylsilyl groups was performed as follows: The lyophilized material was dissolved in 1 mL of 1 M TBAF (THF solution; Aldrich). The solution was left to react for 24 h at room temperature. After dilution with sterile water, oligonucleotides were purified using ion exchange semipreparative chromatography, followed by semipreparative reverse-phase desalting, both performed on the AKTA 900 (GE Healthcare) purifying system, monitored at 260 nm. Protein lysates were harvested 24 h posttreatment, and 500 μg whole-cell extract was subjected to overnight immunoprecipitation with Protein-G-PLUS agarose (Santa Cruz Biotechnology) and 10 μg of Anti-FLAG monoclonal antibody (Sigma). Beads were washed four times in octyl phenoxylpolyethoxylethanol (Nonidet P-40) lysis buffer, and total RNA was extracted with TRIzol (Invitrogen). Northern blot analysis was performed with all harvested total RNA from Flag immunoprecipitation, along with total RNA extracted from 50 μg of whole-cell extract. Phosphatase treatment of svRNA mimetics was performed using 5 μg of RNA with calf intestinal phosphatase (New England Biolabs) for 1 h at 37°C following the manufacturer's instructions. Northern blots were probed as described above with the pan-specific svRNA probe, followed by control U6. The Northern blot depicted in Fig. 3D is representative of three replicate experiments.
qPCR. qPCR was performed on indicated cDNA samples using KAPA SYBR FAST qPCR Master Mix (KAPA Biosystems) and the Mastercycler ep realplex (Eppendorf). We calculated ΔΔCT values over replicates using tubulin as the endogenous housekeeping gene and mock-infected or mock-transfected samples as the calibrator in respective experiments. Values represent the fold difference for each condition as compared with mock-infected or -transfected samples. Error bars indicate ± SD of fold induction. Primers used for qRT-PCR can be found in Table S4 .
Western Blot Analysis. Whole-cell extracts were obtained using standard Nonidet P-40 lysis buffer [0.25% Nonidet P-40 detergent, 50 mM Tris (pH 7.4), 150 mM NaCl, 5 mM EDTA, 10% glycerol, 30 mM NaF, and 40 mM β-glycerophosphate]. Briefly, cell pellets were incubated in lysis buffer for 30 min, and soluble fractions were measured by standard Bradford assay after a 10-min spin at 17,000 × g. We subjected 100 μg of whole-cell extract to SDS/PAGE on 10% polyacrylamide gels. Following electrophoresis, proteins were transferred to Hybond-C nitrocellulose membrane (Amersham) in a buffer containing 30 mM Tris, 200 mM glycine, and 20% methanol for 2 h at 4°C. The membrane was blocked in 5% dried milk in PBS for 1 h at room temperature and then probed with indicated antibodies. Antibodies to A/PR/8/34 HA, NP, and NS1 were all kind gifts from P. Palese (Mount Sinai School of Medicine, New York). Antibodies to retinoic acid-inducible gene I (RIG-I) and PA were kind gifts from A. Garcia-Sastre (Mount Sinai School of Medicine, New York). The antibody for beta-Actin was purchased from AbCam (ab8226-100). Western blots were all developed using the same conditions. Primary antibodies were used at a concentration of 1 μg/mL Incubations were done overnight at 4°C, and incubation mixtures were washed in PBS three times for a total of 15 min. Following washes, the membrane was incubated with peroxidase-conjugated goat anti-rabbit antibody (GE) at a dilution of 1:5,000 for 1 h at room temperature. Following the incubation with the secondary antibody, the membrane was washed again for 15 min and then visualized with the ECL detection system as recommended by the manufacturer (Millipore). Total reads and percentage of reads per segment for influenza A virusspecific and 5′ vRNA-specific (svRNA) captured sequences, and the percentage of each segment's contribution to the total svRNA population. 
